273 related articles for article (PubMed ID: 23647714)
1. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
Hussein Z; Lim-Abrahan MA; Jain AB; Goh SY; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
Latif ZA; Pathan MF; Siddiqui MN; Sobhan MJ; Rahman MM; Ashrafuzzaman SM
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
[TBL] [Abstract][Full Text] [Related]
4. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
Soewondo P; Lindarto D; Wibisono S; Renaldi O; Dalem-Pemayun TG
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
Lim-Abrahan MA; Jain AB; Bebakar WM; Seah D; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of insulin aspart in type 2 diabetic patients: results from the ASEAN cohort of the A₁chieve study.
Bebakar WM; Lim-Abrahan MA; Jain AB; Seah D; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S17-23. PubMed ID: 23647713
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
Soewondo P; Pramono RB; Langi YA; Soetedjo NN; Kshanti IA
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S54-9. PubMed ID: 23647720
[TBL] [Abstract][Full Text] [Related]
8. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
9. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.
El Naggar NK; Soewondo P; Khamseh ME; Chen JW; Haddad J
Diabetes Res Clin Pract; 2012 Dec; 98(3):408-13. PubMed ID: 23217267
[TBL] [Abstract][Full Text] [Related]
10. Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.
Belhadj M; Dahaoui A; Jamoussi H; Farouqi A
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S4-14. PubMed ID: 23958571
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
Almansari A; Khader S; Kharawagh A; AbdelFattah W; Badawy T
Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
Dieuzeide G; Chuang LM; Almaghamsi A; Zilov A; Chen JW; Lavalle-González FJ
Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
[TBL] [Abstract][Full Text] [Related]
14. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
[TBL] [Abstract][Full Text] [Related]
15. Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects.
Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Mahmood S; Vohra EA
J Pak Med Assoc; 2013 Oct; 63(10):1290-4. PubMed ID: 24392563
[TBL] [Abstract][Full Text] [Related]
16. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
18. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study.
Malek R; Arbouche Z; Dahaoui A; Bachaoui M
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S15-26. PubMed ID: 23958568
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
